Revelation Net Debt vs Cash Analysis

REVBW Stock

USD 0.01 0.0001 0.81%

Revelation Biosciences financial indicator trend analysis is much more than just breaking down Revelation Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Revelation Biosciences is a good investment. Please check the relationship between Revelation Biosciences Net Debt and its Cash accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Revelation Stock please use our How to Invest in Revelation Biosciences guide.

Net Debt vs Cash

Net Debt vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Revelation Biosciences Net Debt account and Cash. At this time, the significance of the direction appears to have pay attention.

The correlation between Revelation Biosciences' Net Debt and Cash is -0.88. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Cash in the same time period over historical financial statements of Revelation Biosciences, assuming nothing else is changed. The correlation between historical values of Revelation Biosciences' Net Debt and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Revelation Biosciences are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Net Debt i.e., Revelation Biosciences' Net Debt and Cash go up and down completely randomly.

Correlation Coefficient

-0.88

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Cash

Cash refers to the most liquid asset of Revelation Biosciences, which is listed under current asset account on Revelation Biosciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Revelation Biosciences customers. The amounts must be unrestricted with restricted cash listed in a different Revelation Biosciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Revelation Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Revelation Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Revelation Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Revelation Stock please use our How to Invest in Revelation Biosciences guide.At this time, Revelation Biosciences' Enterprise Value Over EBITDA is fairly stable compared to the past year. Enterprise Value Multiple is likely to climb to 94.48 in 2024, whereas Selling General Administrative is likely to drop slightly above 4.2 M in 2024.

	2010	2022	2023	2024 (projected)
Reconciled Depreciation	16.8K	25.0K	25.0K	24.5K
Cost Of Revenue	69.2K	40.0K	25.0K	35.8K

Reconciled Depreciation Cost Of Revenue

Revelation Biosciences fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Common Stock Shares Outstanding	Total Liab	Net Debt	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Short Long Term Debt Total	Short Term Debt	Current Deferred Revenue
Total Assets		0.82	0.87	0.97	-0.88	0.13	0.13	0.93	0.87	-0.87	0.43	0.7	0.79	0.7	-0.87	-0.93	0.07	0.86	0.38	0.73	-0.11	0.57	-0.93	-0.87	0.92	-0.87
Other Current Liab	0.82		0.99	0.67	-0.96	-0.09	-0.09	0.67	0.99	-0.62	0.17	0.62	0.91	0.62	-0.53	-0.91	0.14	0.99	0.07	0.65	0.05	0.15	-0.9	-0.53	0.9	-0.53
Total Current Liabilities	0.87	0.99		0.73	-0.96	0.02	0.02	0.71	1.0	-0.64	0.22	0.64	0.91	0.64	-0.57	-0.9	0.18	0.98	0.07	0.67	0.07	0.19	-0.9	-0.57	0.89	-0.57
Total Stockholder Equity	0.97	0.67	0.73		-0.73	0.25	0.25	0.93	0.73	-0.9	0.58	0.74	0.62	0.74	-0.88	-0.83	-0.02	0.72	0.52	0.76	-0.21	0.72	-0.84	-0.88	0.82	-0.88
Retained Earnings	-0.88	-0.96	-0.96	-0.73		0.09	0.09	-0.74	-0.96	0.64	-0.1	-0.52	-0.97	-0.52	0.68	0.93	-0.26	-0.97	-0.03	-0.55	-0.13	-0.19	0.92	0.68	-0.93	0.68
Non Current Assets Total	0.13	-0.09	0.02	0.25	0.09		1.0	-0.11	0.02	0.08	0.0	-0.06	-0.16	-0.06	0.1	0.13	-0.08	-0.15	0.03	-0.07	-0.06	-0.01	0.13	0.1	-0.13	0.1
Non Currrent Assets Other	0.13	-0.09	0.02	0.25	0.09	1.0		-0.11	0.02	0.08	0.0	-0.06	-0.16	-0.06	0.1	0.13	-0.08	-0.15	0.03	-0.06	-0.06	-0.01	0.13	0.1	-0.13	0.1
Common Stock Shares Outstanding	0.93	0.67	0.71	0.93	-0.74	-0.11	-0.11		0.71	-0.95	0.63	0.77	0.67	0.77	-0.95	-0.86	0.04	0.76	0.52	0.79	-0.18	0.77	-0.87	-0.95	0.85	-0.95
Total Liab	0.87	0.99	1.0	0.73	-0.96	0.02	0.02	0.71		-0.64	0.22	0.64	0.91	0.64	-0.57	-0.9	0.18	0.98	0.07	0.67	0.07	0.19	-0.9	-0.57	0.89	-0.57
Net Debt	-0.87	-0.62	-0.64	-0.9	0.64	0.08	0.08	-0.95	-0.64		-0.72	-0.88	-0.5	-0.88	0.88	0.85	0.28	-0.69	-0.74	-0.89	0.47	-0.87	0.86	0.88	-0.84	0.88
Accounts Payable	0.43	0.17	0.22	0.58	-0.1	0.0	0.0	0.63	0.22	-0.72		0.84	-0.02	0.84	-0.46	-0.33	-0.31	0.25	0.71	0.83	-0.44	0.85	-0.34	-0.46	0.3	-0.46
Cash	0.7	0.62	0.64	0.74	-0.52	-0.06	-0.06	0.77	0.64	-0.88	0.84		0.36	1.0	-0.57	-0.72	-0.39	0.66	0.71	1.0	-0.52	0.75	-0.73	-0.57	0.7	-0.57
Other Assets	0.79	0.91	0.91	0.62	-0.97	-0.16	-0.16	0.67	0.91	-0.5	-0.02	0.36		0.36	-0.61	-0.82	0.48	0.92	-0.18	0.41	0.36	0.04	-0.82	-0.61	0.83	-0.61
Cash And Short Term Investments	0.7	0.62	0.64	0.74	-0.52	-0.06	-0.06	0.77	0.64	-0.88	0.84	1.0	0.36		-0.57	-0.72	-0.39	0.66	0.71	1.0	-0.52	0.75	-0.73	-0.57	0.7	-0.57
Short Term Investments	-0.87	-0.53	-0.57	-0.88	0.68	0.1	0.1	-0.95	-0.57	0.88	-0.46	-0.57	-0.61	-0.57		0.8	-0.06	-0.63	-0.5	-0.59	0.16	-0.74	0.8	1.0	-0.79	1.0
Non Current Liabilities Total	-0.93	-0.91	-0.9	-0.83	0.93	0.13	0.13	-0.86	-0.9	0.85	-0.33	-0.72	-0.82	-0.72	0.8		0.07	-0.94	-0.4	-0.74	0.22	-0.49	1.0	0.8	-1.0	0.8
Other Current Assets	0.07	0.14	0.18	-0.02	-0.26	-0.08	-0.08	0.04	0.18	0.28	-0.31	-0.39	0.48	-0.39	-0.06	0.07		0.15	-0.79	-0.34	0.97	-0.44	0.07	-0.06	-0.07	-0.06
Other Stockholder Equity	0.86	0.99	0.98	0.72	-0.97	-0.15	-0.15	0.76	0.98	-0.69	0.25	0.66	0.92	0.66	-0.63	-0.94	0.15		0.12	0.7	0.04	0.25	-0.93	-0.63	0.93	-0.63
Net Invested Capital	0.38	0.07	0.07	0.52	-0.03	0.03	0.03	0.52	0.07	-0.74	0.71	0.71	-0.18	0.71	-0.5	-0.4	-0.79	0.12		0.67	-0.91	0.89	-0.41	-0.5	0.39	-0.5
Total Current Assets	0.73	0.65	0.67	0.76	-0.55	-0.07	-0.06	0.79	0.67	-0.89	0.83	1.0	0.41	1.0	-0.59	-0.74	-0.34	0.7	0.67		-0.47	0.74	-0.75	-0.59	0.73	-0.59
Capital Stock	-0.11	0.05	0.07	-0.21	-0.13	-0.06	-0.06	-0.18	0.07	0.47	-0.44	-0.52	0.36	-0.52	0.16	0.22	0.97	0.04	-0.91	-0.47		-0.62	0.23	0.16	-0.22	0.16
Net Working Capital	0.57	0.15	0.19	0.72	-0.19	-0.01	-0.01	0.77	0.19	-0.87	0.85	0.75	0.04	0.75	-0.74	-0.49	-0.44	0.25	0.89	0.74	-0.62		-0.5	-0.74	0.47	-0.74
Common Stock	-0.93	-0.9	-0.9	-0.84	0.92	0.13	0.13	-0.87	-0.9	0.86	-0.34	-0.73	-0.82	-0.73	0.8	1.0	0.07	-0.93	-0.41	-0.75	0.23	-0.5		0.8	-1.0	0.8
Short Long Term Debt Total	-0.87	-0.53	-0.57	-0.88	0.68	0.1	0.1	-0.95	-0.57	0.88	-0.46	-0.57	-0.61	-0.57	1.0	0.8	-0.06	-0.63	-0.5	-0.59	0.16	-0.74	0.8		-0.79	1.0
Short Term Debt	0.92	0.9	0.89	0.82	-0.93	-0.13	-0.13	0.85	0.89	-0.84	0.3	0.7	0.83	0.7	-0.79	-1.0	-0.07	0.93	0.39	0.73	-0.22	0.47	-1.0	-0.79		-0.79
Current Deferred Revenue	-0.87	-0.53	-0.57	-0.88	0.68	0.1	0.1	-0.95	-0.57	0.88	-0.46	-0.57	-0.61	-0.57	1.0	0.8	-0.06	-0.63	-0.5	-0.59	0.16	-0.74	0.8	1.0	-0.79

Click cells to compare fundamentals

Revelation Biosciences Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Revelation Stock Analysis

When running Revelation Biosciences' price analysis, check to measure Revelation Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Revelation Biosciences is operating at the current time. Most of Revelation Biosciences' value examination focuses on studying past and present price action to predict the probability of Revelation Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Revelation Biosciences' price. Additionally, you may evaluate how the addition of Revelation Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Revelation Net Debt vs Cash Analysis

Net Debt vs Cash

Net Debt vs Cash Correlation Analysis

Correlation Coefficient

Net Debt

Cash

Revelation Biosciences fundamental ratios Correlations

Revelation Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Revelation Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Current Liabilities
Non Currrent Assets Other	+ 1.0	Non Current Assets Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Long Term Debt Total	+ 1.0	Short Term Investments

Short Term Debt	- 1.0	Common Stock
Short Term Debt	- 1.0	Non Current Liabilities Total
Other Stockholder Equity	- 0.97	Retained Earnings
Other Assets	- 0.97	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Total Current Liabilities